What Happened?
Norcross, GA-based Galectin-Therapeutics Appointed Joel Lewis as Chief Executive Officer and President
About the Company
Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company`s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.
About the Person
Joel Lewis is Chief Executive Officer and President at Galectin Therapeutics. Previously, Joel held various senior HR leadership roles in the industry.
Info Source
News
Short Profile